Recently, Beijing Health Guard Biotechnology, Inc. (hereinafter, BHGB) received the DSMB’s (Data and Safety Monitoring Board) Recommendation with respect to the first primary endpoint analysis in the Phase III clinical trial in Indonesia of its in-house developed recombinant Nonavalent HPV Vaccine, which is made based on the data readout from the analysis. As indicated in the Recommendation letter, the review by the DSMB of available safety and immunogenicity data, as well as quality of the study finds that the investigational vaccine has an acceptable safety profile and the trial meets the pre-specified primary immunogenicity endpoint; therefore, the DSMB recommends the study proceed as per the current study protocol.